ストックスクリーナーアプリを入手
0.831
4.14%
-0.0359
アフターアワーズ：
.85
0.019
+2.29%
前日終値:
$0.8669
開ける：
$0.8736
24時間の取引高:
65,756
Relative Volume:
0.06
時価総額：
$697.03K
収益：
$104.00K
当期純損益:
$-8.06M
株価収益率:
-0.0126
EPS:
-65.9194
ネットキャッシュフロー:
$-14.30M
1週間 パフォーマンス:
-8.28%
1か月 パフォーマンス:
-23.06%
6か月 パフォーマンス:
-86.20%
1年 パフォーマンス:
-95.82%
1日の値動き範囲:
$0.8158
$0.8736
1週間の範囲:
$0.8118
$0.9799
52週間の値動き範囲:
$0.8118
$26.50
Biodexa Pharmaceuticals Plc Adr Stock (BDRX) Company Profile
Compare BDRX vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BDRX
Biodexa Pharmaceuticals Plc Adr
|
0.831 | 727.14K | 104.00K | -8.06M | -14.30M | -65.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Biodexa Pharmaceuticals Plc Adr Stock (BDRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-02-08 | 開始されました | Ladenburg Thalmann | Buy |
Biodexa Pharmaceuticals Plc Adr (BDRX) 最新ニュース
Biodexa Pharmaceuticals (NASDAQ:BDRX) Upgraded at Wall Street Zen - Defense World
Biodexa Licenses Phase 1 Ready Drug Candidate from Otsuka for Rare Stomach Cancer - Finviz
BDRX SEC FilingsBiodexa Pharmaceuticals plc 10-K, 10-Q, 8-K Forms - Stock Titan
Biodexa Announces Exclusive License of Otsuka’s OPB-171775, a potent Phase 1 ready Molecular Glue for GIST - markets.businessinsider.com
Biodexa licenses Otsuka’s molecular glue compound for GIST treatment By Investing.com - Investing.com India
Biodexa licenses Otsuka’s molecular glue compound for GIST treatment - Investing.com
Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) Short Interest Update - Defense World
Biodexa Pharmaceuticals promotes Fiona Sharp to CFO, secretary - Yahoo Finance
Biodexa pharmaceuticals appoints Fiona Sharp as CFO and board member By Investing.com - Investing.com India
Biodexa pharmaceuticals appoints Fiona Sharp as CFO and board member - Investing.com
Biodexa Pharmaceuticals Faces Market Challenges as Stocks Decline - StocksToTrade
Short Interest in Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) Expands By 298.4% - Defense World
Biodexa Pharmaceuticals prices 157,000 units at $3.28 in public offering - TipRanks
Biodexa Pharmaceuticals stock falls after $10 million public offering By Investing.com - Investing.com South Africa
Biodexa Pharmaceuticals stock falls after $10 million public offering - Investing.com
Biodexa prices $10 million public offering of units and warrants - Investing.com
Biodexa prices $10 million public offering to fund development programs - Investing.com
Biodexa prices $10 million public offering to fund development programs By Investing.com - Investing.com UK
Why B. Riley Financial Shares Are Trading Higher By Around 25%; Here Are 20 Stocks Moving Premarket - Benzinga
Biodexa Pharmaceuticals (NASDAQ:BDRX) Shares Down 53.8% – Time to Sell? - Defense World
Biodexa Pharmaceuticals (NASDAQ: BDRX) Stock on December 10, 2025: Violent Rally, Phase 3 FAP Progress and What 2026 Might Hold - ts2.tech
Biodexa Pharmaceuticals Stock Surges: What’s Next? - timothysykes.com
Wall Street analysts’ outlook for Biodexa Pharmaceuticals Plc ADR (BDRX) - setenews.com
Biodexa Pharmaceuticals (NASDAQ: BDRX) outlines major unit deal with complex zero-cash warrants - Stock Titan
Biodexa enrolls first European patients in phase 3 FAP trial By Investing.com - Investing.com South Africa
Biodexa enrolls first European patients in phase 3 FAP trial - Investing.com
EBIT per share of Biodexa Pharmaceuticals plc Sponsored ADR – FWB:5MP - TradingView
[424B3] Biodexa Pharmaceuticals Plc Prospectus Filed Pursuant to Rule 424(b)(3) - Stock Titan
Biodexa activates first European site for phase 3 FAP trial By Investing.com - Investing.com India
Biodexa activates first European site for phase 3 FAP trial - Investing.com
Biodexa Pharmaceuticals plc (BDRX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Biodexa Pharmaceuticals (NASDAQ:BDRX) Stock Price Down 0.4% – What’s Next? - Defense World
[POS AM] Biodexa Pharmaceuticals Plc SEC Filing - Stock Titan
Total debt per share of Biodexa Pharmaceuticals plc Sponsored ADR – BER:5MP - TradingView
What Makes Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) a New Buy Stock - MSN
Holdings of Biodexa Pharmaceuticals Plc ADR (BDRX) are aligned with the stars - setenews.com
Biodexa receives EMA approval for phase 3 FAP treatment trial - Investing.com India
Biodexa (NASDAQ: BDRX) sets first EU enrollment for 4Q 2025 after EMA CTA approval - Stock Titan
Biodexa Pharmaceuticals (NASDAQ:BDRX) Stock Price Up 5.7% – Time to Buy? - Defense World
Biodexa Pharmaceuticals (NASDAQ:BDRX) Given Sell (E+) Rating at Weiss Ratings - Defense World
Why Did Biodexa Pharmaceuticals' Stock Drop After-Hours Despite Big Gain During Regular Trading? - inkl
Biodexa Hosts Breakfast Symposium on FAP Mechanisms and Chemoprevention at CGA‑IGC in October 2025 - Stock Titan
Short Interest in Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) Decreases By 53.3% - Defense World
Interim results for the six months ended June 30, 2025 - GlobeNewswire
Biodexa Pharmaceuticals reports 1H EPS (GBP0.0002) vs. (GBP0.001) last year - TipRanks
Biodexa says requirement for financing represents ‘material uncertainty’ - TipRanks
First Patients Enrolled: Biodexa's Breakthrough FAP Treatment Advances to Pivotal Phase 3 Trial with $35M Backing - Stock Titan
Biodexa begins phase 3 trial of FAP treatment with $20M funding By Investing.com - Investing.com South Africa
Biodexa begins phase 3 trial of FAP treatment with $20M funding - Investing.com Nigeria
$7 Billion Untapped Market: Biodexa's eRapa Could Be First FDA-Approved Drug for Devastating FAP Disease - Stock Titan
Biodexa Moves Into Phase 3 With eRapa For FAP With First Patients Enrolled - Finviz
Biodexa Pharmaceuticals Plc Adr (BDRX) 財務データ
収益
当期純利益
現金流量
EPS
0.48%
1.21%
大文字化:
|
ボリューム (24 時間):